Senator Cory A. Booker (Democratic-New Jersey) recently sold shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). In a filing disclosed on September 09th, the Senator disclosed that they had sold between $1,001 and $15,000 in Alnylam Pharmaceuticals stock on August 11th.
Senator Cory A. Booker also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 8/11/2026.
- Sold $15,001 – $50,000 in shares of McDonald’s (NYSE:MCD) on 8/11/2026.
- Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/11/2026.
- Sold $1,001 – $15,000 in shares of JD.com (NASDAQ:JD) on 8/11/2026.
- Sold $100,001 – $250,000 in shares of Amazon.com (NASDAQ:AMZN) on 8/11/2026.
Alnylam Pharmaceuticals Trading Up 0.5%
Shares of Alnylam Pharmaceuticals stock traded up $1.17 on Friday, reaching $248.68. 1,177,278 shares of the company were exchanged, compared to its average volume of 1,659,503. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The firm has a market capitalization of $33.28 billion, a price-to-earnings ratio of 46.22 and a beta of 0.31. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The stock has a fifty day moving average price of $254.43 and a 200-day moving average price of $288.99.
Institutional Trading of Alnylam Pharmaceuticals
A number of hedge funds have recently made changes to their positions in ALNY. MV Capital Management Inc. purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $29,000. HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $27,000. Golden State Wealth Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 36 shares during the period. Finally, Manchester Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 72 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts have commented on the stock. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. Chardan Capital restated a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Stifel Nicolaus reduced their price target on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Truist Financial decreased their price objective on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Finally, Citigroup cut their target price on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $376.67.
Read Our Latest Stock Analysis on ALNY
About Senator Booker
Cory Booker (Democratic Party) is a member of the U.S. Senate from New Jersey. He assumed office on October 31, 2013. His current term ends on January 3, 2027. Booker (Democratic Party) ran for re-election to the U.S. Senate to represent New Jersey. He won in the general election on November 3, 2020. Booker also ran for election for President of the United States. He did not appear on the ballot for the Democratic convention on August 18, 2020. Booker announced that he was running for president of the United States on February 1, 2019. He suspended his presidential campaign on January 13, 2020. Before being elected to the Senate, Booker served as the 36th mayor of Newark. He also served on the Newark City Council for the Central Ward. In September 2017, he was rated the third most liberal senator based on his voting record, according to The New York Times. Booker was born in 1969 in Washington, D.C., and grew up in Harrington Park, New Jersey. He attended Stanford University on a varsity football scholarship, receiving a B.A. in 1991 and an M.A. in 1992. Booker was a Rhodes Scholar at the University of Oxford, where he earned a graduate degree in history in 1994. He then attended Yale Law School, graduating with a J.D. in 1997. After completing his education, Booker moved into a public housing project in Newark, New Jersey, became a tenant organizer, and founded a nonprofit that provided legal assistance to low-income families. He was elected to the Newark City Council in 1998 and served there until 2002, when he ran unsuccessfully for mayor. The same year, he became a partner at Booker, Rabinowitz, Trenk, Lubetkin, Tully, DiPasquale & Webster. In 2006, Booker ran again for mayor of Newark and was elected with 72% of the vote. He served as mayor until 2013. On October 16, 2013, Booker won a special election to the U.S. Senate after the death of Sen. Frank Lautenberg (D). Booker was re-elected to the U.S. Senate on November 4, 2014. In 2016, Booker published a memoir titled United: Thoughts on Finding Common Ground and Advancing the Common Good.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).
Featured Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
